You just read:

ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients

News provided by

Transave, Inc.

Oct 21, 2010, 11:30 ET